Video Interview: Michael W. Belin, MD, on Epion’s Phase 3 Epi-On Cross-Linking Trials
“What really makes the study unique is that we are treating the widest spectrum of disease.”
In an interview with Eyewire+, Michael W. Belin, MD, Chief Medical Officer of Epion Therapeutics, discusses the design and progress of Epion’s Phase 3 clinical trials evaluating epithelium-on corneal cross-linking in keratoconus patients ages 8 to 45. Dr. Belin highlights the study’s unique ability to treat a broad spectrum of disease — from subclinical to advanced keratoconus — using standardized tomographic criteria, with the option for treatment at diagnosis and simultaneous bilateral treatment when appropriate. He also outlines the trials’ sham-controlled design, safety-focused approach, and current enrollment progress as Epion advances toward study completion.